Gasherbrum Bio registers Phase 1 hepatic impairment study for aleniglipron
Structure Therapeutics subsidiary lists a new single-dose PK trial examining aleniglipron in people with liver impairment, not yet recruiting.
One registry update for the week concerns a new early-phase trial of aleniglipron.
- Gasherbrum Bio, Inc., described in the registry as a wholly owned subsidiary of Structure Therapeutics1, registered a Phase 1 study titled "A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics." The trial is listed as not yet recruiting, with an estimated start of October 2026 and estimated primary completion in August 20271. It plans to enroll 36 participants1 across two sites in the United States, in Orlando, Florida and San Antonio, Texas1, with the main goal of assessing pharmacokinetics of aleniglipron in participants with hepatic impairment to establish scientifically guided dosing recommendations1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.